SCHEMBL3326973

SCHEMBL3326973

CC(C)=CCOc1ccc2oc3ccccc3c(=O)c2c1OCC=C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.50
RXRA P19793 1/20 0.47
IKBKB O14920 1/20 0.46
MAOA P21397 3/20 0.46
PPARG P37231 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
MGAM O43451 2/20 0.43
GAA P10253 2/20 0.43
SI P14410 2/20 0.43
PTPN1 P18031 2/20 0.43
MGAM2 Q2M2H8 2/20 0.43
VKORC1 Q9BQB6 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
ACHE P22303 1/20 0.42
CYP1B1 Q16678 1/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29833663 0.79 MAOA (0.52) MAOAALDH1A1KDM4ECYP3A4HPGD
SCHEMBL644478 0.79 MAOA (0.52) MAOAALDH1A1KDM4ECYP3A4HPGD
SCHEMBL7073740 0.76 MAOA (0.51) ALOX15IKBKBMAOAPTGS2VKORC1
SCHEMBL30255441 0.72 MAOA (0.69) MAOAMGAMALDH1A1LMNAKDM4E
SCHEMBL5612997 0.72 MAOA (0.69) MAOAMGAMALDH1A1LMNAKDM4E
SCHEMBL2052448 0.71 IKBKB (0.58) IKBKBMAOAMGAMGAASI
SCHEMBL3130212 0.71 IKBKB (0.61) IKBKBMAOAPTGS1PTGS2MGAM
SCHEMBL1857089 0.70 ALOX15 (0.52) ALOX15IKBKBPPARGPTGS1GAA
SCHEMBL7072951 0.69 MAOB (0.45) ALOX15MAOALMNAKDM4EHPGD
SCHEMBL29287875 0.69 MAOA (0.52) MAOAALDH1A1LMNAKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137421-A1 SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2010-06-03 US disclosed
WO-2008057604-A9 SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE UNIV CALIFORNIA (US) 2008-10-02 WO disclosed
WO-2008057604-A2 SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137421-A1 SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE BAD, CASP3, BID ALOX15 2223/4885RXRA 3637/4885IKBKB 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.